Home Systems biology GeneCentric to Present Data on Tumor Purity Independent Subtyping Assay (PurIST℠) at AACR Pancreatic Conference

GeneCentric to Present Data on Tumor Purity Independent Subtyping Assay (PurIST℠) at AACR Pancreatic Conference


DURHAM, NC–(BUSINESS WIRE)–GeneCentric Therapeutics, a company making precision medicine more accurate through RNA-based diagnostics, today announced a poster presentation of additional clinical validation data for PurIST℠, a novel RNA expression assay, in collaboration with Tempus. PurIST identifies patients with the classic pancreatic ductal adenocarcinoma (PDAC) subtype who are likely to experience longer overall survival (OS) with the FOLFIRINOX standard of care (SOC) than patients with the basal subtype of PDAC. The presentation will be made at the AACR’s 8th Special Conference on Pancreatic Cancer in Boston, Massachusetts, September 13-16, 2022.

Title: Purity Independent Subtyping of Tumor (PurIST): real-world data validation of a pancreatic ductal adenocarcinoma (PDAC) gene expression classifier and its prognostic implications

First author: Stephane Wenric, PhD, Principal Investigator, Computational Systems Biology, Tempus, Chicago, Illinois

Speaker: James M. Davison, PhD, Senior Translational Genomics Scientist, GeneCentric Therapeutics, Durham, NC

Session: Poster Session A

Poster number: A002

Date: September 13, 2022

Time: 7:30 p.m. to 9:00 p.m. EDT

PurIST is a laboratory-developed test (LDT) validated by Tempus using an advanced PDAC real patient data set. Over 250 patients with advanced PDAC who were previously treated with SOC FOLFIRINOX or gemcitabine/nab-paclitaxel have been identified in Tempus’ multimodal database. RNA sequencing (RNAseq) was performed on primary or metastatic tumor tissues using the CAP/CLIA validated Tempus xT assay platform. Patients were identified as basal or classical molecular subtype. For patients treated with FOLFIRINOX, those with a classical molecular subtype had prolonged survival compared to those with a basal molecular subtype. Survival was similar for FOLFIRINOX and gemcitabine/nab-paclitaxel regimens in basal patients, but classic patients had prolonged survival when treated with FOLFIRINOX.

Further details regarding the development and validation of the tests will be presented in a forthcoming publication.

About pancreatic cancer

Pancreatic cancer is one of the most common cancers in the world, and the National Cancer Institute estimates that there will be 62,210 new cases and 49,830 deaths in the United States in 2022. This is the third leading cause of cancer-related death in the United States and has the highest mortality rate of all major cancers. Over 90% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDACs), and the 5-year overall survival for resectable/borderline and unresectable PDACs is approximately 20-30% and 1-3 %, respectively. The average patient diagnosed with stage IV PDAC will live approximately one year after diagnosis. The three main treatments for PDAC are surgical resection (if diagnosed early), radiation therapy, and chemotherapy. For resectable tumours, surgical resection is planned for curative intent, however, for unresectable tumours, chemotherapy such as FOLFIRINOX or gemcitabine with nab-paclitaxel is often used.

About GeneCentric

GeneCentric Therapeutics, Inc. is an RNA-based genomics solutions provider based in Durham, NC. The Company has designed its technologies to analyze the complexity of tumor and immune biology using its RNA-based Tumor and Immune Microenvironment Exploration (rT(I)ME) platform to discover and develop signatures of populations of responders to oncological therapies. GeneCentric commercializes its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostic companies in applications throughout the preclinical testing, clinical drug development and commercialization phases. For more information, visit www.genecentric.com or follow us on LinkedIn.